Production (Stage)
Foghorn Therapeutics Inc.
FHTX
$4.32
-$0.22-4.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.46% | 11.99% | 11.61% | 24.59% | 17.34% |
| Total Depreciation and Amortization | -9.19% | -9.59% | -6.85% | -2.45% | 1.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.17% | -18.07% | -15.49% | 0.90% | -2.18% |
| Change in Net Operating Assets | 27.55% | 22.95% | 18.65% | -128.14% | -144.30% |
| Cash from Operations | 18.27% | 14.99% | 13.44% | 2.34% | -6.57% |
| Capital Expenditure | -20.90% | 25.98% | 68.13% | 86.09% | 56.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -200.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -118.75% | -119.91% | -114.06% | -22.49% | 365.25% |
| Cash from Investing | -119.43% | -120.70% | -114.73% | -21.49% | 356.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,592.75% | 5,862.49% | 6,504.17% | 19,059.03% | 91.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,572.18% | 5,829.58% | 6,467.79% | 19,023.83% | 91.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -163.70% | -188.48% | 27.10% | 2,402.83% | 117.55% |